119 related articles for article (PubMed ID: 3976784)
1. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.
Ottosson UB; Johansson BG; von Schoultz B
Am J Obstet Gynecol; 1985 Mar; 151(6):746-50. PubMed ID: 3976784
[TBL] [Abstract][Full Text] [Related]
2. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins.
Ottosson UB
Acta Obstet Gynecol Scand Suppl; 1984; 127():1-37. PubMed ID: 6596830
[TBL] [Abstract][Full Text] [Related]
3. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I.
Miller VT; Muesing RA; LaRosa JC; Stoy DB; Phillips EA; Stillman RJ
Obstet Gynecol; 1991 Feb; 77(2):235-40. PubMed ID: 1846437
[TBL] [Abstract][Full Text] [Related]
4. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women.
Paganini-Hill A; Dworsky R; Krauss RM
Am J Obstet Gynecol; 1996 Mar; 174(3):897-902. PubMed ID: 8633665
[TBL] [Abstract][Full Text] [Related]
6. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
[TBL] [Abstract][Full Text] [Related]
7. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone.
Chen FP; Lee N; Soong YK
J Reprod Med; 1998 Jul; 43(7):568-74. PubMed ID: 9693406
[TBL] [Abstract][Full Text] [Related]
8. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
9. Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel.
Vejtorp M; Christensen MS; Vejtorp L; Larsen JF
Acta Obstet Gynecol Scand; 1986; 65(5):391-5. PubMed ID: 3535357
[TBL] [Abstract][Full Text] [Related]
10. Effects of an antiestrogen on subfractions of HDL cholesterol during estrogen replacement therapy.
Ottosson UB; Carlström K; Johansson BG; von Schoultz B
Gynecol Obstet Invest; 1984; 18(3):140-6. PubMed ID: 6436151
[TBL] [Abstract][Full Text] [Related]
11. Estrogen induction of liver proteins and high-density lipoprotein cholesterol: comparison between estradiol valerate and ethinyl estradiol.
Ottosson UB; Carlström K; Johansson BG; von Schoultz B
Gynecol Obstet Invest; 1986; 22(4):198-205. PubMed ID: 3817605
[TBL] [Abstract][Full Text] [Related]
12. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
Hargrove JT; Maxson WS; Wentz AC; Burnett LS
Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hormone replacement therapy and plasma lipoproteins.
Taskinen MR
J Intern Med; 1995 Nov; 238(5):385-7. PubMed ID: 7595177
[No Abstract] [Full Text] [Related]
14. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
Barnes RB; Roy S; Lobo RA
Obstet Gynecol; 1985 Aug; 66(2):216-9. PubMed ID: 2991832
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hormone replacement therapy on blood serum lipids in postmenopausal women with type 2 diabetes].
Kozlov SG; Dotsenko IuV; Sankova AV; Liakishev AA; Tvorogova MG; Afanas'eva OI; Titov VN; Pokrovskiĭ SN; Naumov VG
Kardiologiia; 2002; 42(7):47-52. PubMed ID: 12494113
[TBL] [Abstract][Full Text] [Related]
16. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens.
Yancey MK; Hannan CJ; Plymate SR; Stone IK; Friedl KE; Wright JR
Fertil Steril; 1990 Nov; 54(5):778-82. PubMed ID: 2226911
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
[TBL] [Abstract][Full Text] [Related]
18. Comparison of norgestrel- versus cyproterone acetate-containing hormone replacement therapy on lipid-lipoprotein metabolism.
Panyakhamlerd K; Limpaphayom K; Taechakraichana N; Chaikittisilpa S; Pasatrat S; Pojanasopanakun S
J Med Assoc Thai; 2000 Jul; 83(7):764-70. PubMed ID: 10932511
[TBL] [Abstract][Full Text] [Related]
19. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R
Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833
[TBL] [Abstract][Full Text] [Related]
20. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
